Atombeat and BioDuro have announced a strategic partnership to launch an AI-powered platform aimed at accelerating peptide drug discovery.

Regeneron has received an US Food and Drug Administration (FDA) rejection for a new blood cancer therapy and expects separate regulatory delays for blockbuster ophthalmology drug Eylea HD due to ...

Computational chemistry combined with AI technologies has become a powerful tool for assessing small molecule properties, ...

The beginning of August marks the latest deadline for US president Donald Trump’s “liberation day” tariff policy. This era of ...

India and the United Kingdom recently signed a Comprehensive Economic and Trade Agreement (CETA), but could it solve the ...